Utility of FDG-PET/CT in follow-up of children treated for hodgkin and non-hodgkin lymphoma

Journal of Pediatric Hematology/Oncology

Volumn 28, Issue 5, 2006, Pages 300-306

  Rhodes, Melissa M ^a   Delbeke, Dominique ^a   Whitlock, James A ^a   Martin, William ^a   Kuttesch, John F ^a   Frangoul, Haydar A ^a   Shankar, Sadhna ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b 397 PRB ^*  (United States)

Author keywords

Child; FDG PET; Lymphoma

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADOLESCENT; ADULT; ARTICLE; CANCER RECURRENCE; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; LIVER; MALE; MEDICAL RECORD; NONHODGKIN LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SECOND CANCER; TREATMENT OUTCOME;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DIAGNOSTIC ERRORS; FEMALE; FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; POSITRON-EMISSION TOMOGRAPHY; RECURRENCE; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 33745282725     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/01.mph.0000212912.37512.b1     Document Type: Article

References (39)

1. Percy CL, Smith MA, Linet M, et al. Lymphomas and reticulo-endothelial neoplasms. In: Ries LAG, Smith MA, Gurney JG, et al eds. Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975-1995. NIH Pub. No. 99-4649. Bethesda, MD: National Cancer Institute, SEER Program; 1999.
2. Front D, Ben-Haim S, Israel O, et al. Lymphoma: Predictive value of Ga-167 scintigraphy after treatment. Radiology. 1992;182:359-363.
3. Delbeke D, Martin WH. Positron emission tomography imagining in oncology. Radiol Clin North Am. 2001;39:883-917.
4. Divgi C. Imaging: Staging and evaluation of lymphoma using nuclear medicine. Semin Oncol. 2005;32:S11-S18.
5. Som P, Atkins HL, Bandoypadhyay D, et al. A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): Nontoxic tracer for rapid tumor detection. J Nucl Med. 1980;21:670-675.
6. Delbeke D, Martin WH, Morgan DS, et al. 2-deoxy-2-[F-18]fluoro-D-glucose imaging with positron emission tomography for initial staging in Hodgkin disease and lymphoma. Mol Imaging Biol. 2002;4:105-114.
7. Menzel C, Dobert N, Mitrou P, et al. Positron emission tomography for the staging of Hodgkin lymphoma: Increasing the body of evidence in favor of the method. Acta Oncol. 2002;41:430-436.
8. Rini JN, Leonidas JC, Tomas MB, et al. 18F-FDG PET versus CT for evaluating the spleen during initial staging of lymphoma. J Nucl Med. 2003;44:1072-1074.
9. Foo SS, Mitchell PL, Berlangieri SU, et al. Positron emission tomography scanning in the assessment of patient with lymphoma. Intern Med J. 2004;34:388-397.
10. Schaefer NG, Hany TF, Taverna C, et al. Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT staging and restaging: Do we need contrast-enhanced CT? Radiology. 2004;232:823-829.
11. Munker R, Glass J, Griffeth LK, et al. Contribution of PET imaging to the initial staging and prognosis of patients with Hodgkin disease. Ann Oncol. 2004;15:1699-1704.
12. Naumann R, Beuthien-Baumann B, Reiss A, et al. Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin lymphoma. Br J Cancer. 2004;90:620-625.
13. Lin P, Kneebone A, Moylan E, et al. Direct comparison of 18F-fluorodeoxyglucose coincidence gamma camera tomography with gallium scanning for the staging of lymphoma. Intern Med J. 2005;35:91-96.
14. 18F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? BJH. 2002;115:272-278.
15. Lavely WC, Delbeke D, Greer JP, et al. FDG PET in the follow-up management of patients with newly diagnosed Hodgkin and non-Hodgkin lymphoma after first-line chemotherapy. Int J Radiation Oncology Biol Phys. 2003;57:307-315.
16. 18F-FDG in Hodgkin disease for posttreatment evaluation. J Nucl Med. 2003;44:1225-1231.
17. Torizuka T, Nakamura F, Kanno T, et al. Early therapy monitoring with FDG-PET in aggressive non-Hodgkin lymphoma and Hodgkin lymphoma. Eur J Med Mol Imaging. 2004;31:22-28.
18. Avril NE, Weber WA. Monitoring response to treatment in patients utilizing PET. Radiol Clin North Am. 2005;43:189-204.
19. 18F]fluoro-2-deoxy-D- glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood. 2005, Apr 28 [Epub].
20. 18F]FDG in childhood lymphoma: clinical utility and impact on management. Eur J Nucl Med. 2002;29:1155-1165.
21. Wickmann L, Luders H, Dorffel W. 18-FDG-PET findings in children and adolescents with Hodgkin disease: Retrospective evaluation of the correlation to other imaging procedures in initial staging and to the predictive value of follow up evaluations. Klin Pediatr. 2003;215:146-150.
22. Korholz D, Kluge R, Wickmann L, et al. Importance of F18-fluorodeoxy-D-2- glucose positron emission tomography (FDG-PET) for staging and therapy control of Hodgkin lymphoma in childhood and adolescence: Consequences for the GPOH-HD 2003 protocol. Onkologie. 2003;26:489-493.
23. Hudson MM, Krasin MJ, Kaste SC. PET imaging in pediatric Hodgkin lymphoma. Pediatr Radiol. 2004;34:190-198.
24. Hermann S, Wormanns D, Pixberg M, et al. Staging in childhood lymphoma: differences between FDG-PET and CT. Nuklearmedizin. 2005;44:1-7.
25. 18F-FDG PET in children with lymphomas. Eur J Nucl Med Mol Imaging. 2005;32:31-38.
26. 18F-Fluorodeoxyglucose for the evaluation of residual Hodgkin disease mediastinal masses. Leuk Lymphoma. 2004;45:1829-1833.
27. Castelluci P, Zinzani P, Pourdehnad M, et al. (18)F-FDG PET in malignant lymphoma: significance of positive findings. Eur J Nucl Med Mol Imaging. 2005; Mar 23 [Epub].
28. Jerusalem G, Beguin Y, Fassotte MF, et al. Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin disease. Ann Oncol. 2003;14:123-130.
29. Zhuang H, Yu JQ, Alavi A. Applications of fluorodeoxyglucose-PET imaging in the detection of infection and inflammation and other benign disorders. Radiol Clin North Am. 2005;43:121-134.
30. Srinivasan R, Filie A, Reynolds J, et al. Positron emission tomography for lymphoma staging: tissue remains the issue. J Natl Cancer Inst. 2005;97:611-613.
31. Siosteen A, Fredrick C, Jacobsson H. FDG uptake in a catheter-related thrombus simulating relapse of lymphoma. Clin Nucl Med. 2005;30:338-339.
32. 18F-FDG PET early after radiotherapy in lymphoma patients. Cancer Biother Radiopharm. 2004;19:606-612.
33. 18F-FDG PET after chemotherapy for primary diffuse large B-cell lymphoma of the thyroid: A case report. Jpn J Clin Oncol. 2004;34:280-281.
34. Bhargava P, Zhuang H, Kumar R, et al. Iatrogenic artifacts on whole-body F-18 FDG PET imaging. Clin Nucl Med. 2004;29:429-439.
35. Jeong W, Seiter K, Strauchen J, et al. PET scan-positive cat scratch disease in a patient with T cell lymphoblastic lymphoma. Leuk Res. 2005;29:591-594.
36. Mackie GC. F-18 fluorodeoxyglucose positron emission tomographic imaging of cytomegalovirus pneumonia. Clin Nucl Med. 2004;29:569-571.
37. Chen YK, Shen YY, Kao CH. Abnormal FDG PET imaging in tuberculosis appearing like lymphoma. Clin Nucl Med. 2004;29:124.
38. Hillner BE, Tunuguntla R, Fratkin M. Clinical decisions associated with positron emission tomography in a prospective cohort of patients with suspected or known cancer at one United States center. J Clin Oncol. 2004;22:4147-4156.
39. Wegner EA, Barrington SF, Kingston JE, et al. The impact of PET scanning on management of paediatric oncology patients. Eur J Nucl Med Mol Imaging. 2005;32:23-30.